Utility of Cell Saver in Trauma Compared to Cardiac Surgery

B Couch, BS, E Kim, MBA, K Shrestha, MBBS, S Dhanasekara, MBBS, PhD, A Sabu-Kurian, BS, S Dissanaike, MD

Texas Tech University Health Sciences Center School of Medicine

Background: While reperfusion of autologous blood using the Cellsaver (CS) device is routine in cardiothoracic surgery, it is still only used intermittently, with a paucity of evidence-based literature, in trauma. We compared the utility of CS in these two distinct populations within the same institution, to explore current status as well as the potential benefit of greater CS use in trauma.


Methods: Retrospective review of CS use at a Level 1 trauma center 2017-2022. Volume of blood salvaged, reinfused, total and allogenic blood transfusion volume were compared between trauma (general & orthopedic) & cardiac surgery cases. Cost of CS deployment & auto-transfusion was compared to cost of allogenic blood from blood bank. Winsorized data was analyzed via Kruskal Wallis tests and χ^2 tests with multiple pairwise comparisons. Family-wise error rate maintained at 0.05.

Table 1. Baseline characteristics	s and outcomes (Card	iac vs Trauma)	
	Cardiac Surgery (n	Trauma Surgery (n	p-value
	= 1215) median	= 325) median	
	(IQR) /n (%)	(IQR) /n (%)	
Age	64 (14.8)	38.5 (29)	< 0.001
Male Sex	857 (70.6)	245 (75.4)	0.103
Cases w/ successful CS	1200 (98.8)	310 (95.4)	0.001
retrieval of blood			
Cases w/ successful CS	1181 (97.3)	239 (74)	< 0.001
transfusion			
Volume of salvaged blood	500 (275)	250 (585)	< 0.001
received (ml)			
Percentage of CS transfusion	73.2 ± 31.6	36.8 ± 35.5	< 0.001
from total volume of			
transfusion*			
Volume of allogenic blood	0 (600)	650 (1500)	< 0.001
received			
Cases w/ allogenic blood	546 (44.9)	227 (69.9)	< 0.001
received			
Total transfusion cost	150 (360)	540 (887)	< 0.001
Cost for allogenic blood	0 (360)	390 (900)	< 0.001
transfusion			
*mean + standard deviation			

Table 2. Baseline charac		omes (Cardiac vs		pedic)
	Cardiac	General	Orthopedic	p-value
	Surgery (n =	Surgery (n =	surgery (n =	
	1215) median	197) median	128) median	
	(IQR) /n (%)	(IQR) /n (%)	(IQR) /n (%)	
Age	64 (14.75) ^a	39 (38) ^b	26 (37) ^b	< 0.001
Male Sex	857 (70.6)	143 (72.5)	102 (79.7)	0.090
Cases w/ successful	1200 (98.76) ^a	189 (95.9) ^b	121 (94.5) ^b	0.001
CS retrieval of blood				
Cases w/ successful	1181 (97.28)	145 (74.4)	94 (73.4)	< 0.001
CS transfusion				
Volume of salvaged	500 (275) ^a	244 (450) ^b	467 (1066.25) ^a	< 0.001
blood received (ml)				
Percentage of CS	73.15 ± 31.63 ^a	41.99 ± 39.12 ^b	29.00 ± 27.46 ^c	< 0.001
transfusion from total				
volume of transfusion				
Volume of allogenic	0 (600) ^a	300 (1400) ^b	900 (1742.5) ^c	< 0.001
blood received				
Cases w/ allogenic	546 (44.93) ^a	114 (57.9) ^b	113 (88.3) ^c	< 0.001
blood received				
Total transfusion cost	150 (360) ^a	330 (945) ^a	480 (1047.2) ^b	< 0.001
Cost for allogenic	0 (360) ^a	300 (1400) ^b	900 (1742.5) ^c	< 0.001
blood transfusion				
*mean ± standard deviate; values with different superscripts in a row are significantly				
different using post-hoc comparisons with Holm-Bonferroni correction.				
01				

Table 3. Interaction model predicting volume of allogenic blood transfusion and total				
cost related to blood transfusion in trauma group.				
	Estimate	SE	t-value	p-value

	Estimate	5E	t-value	p-value
DV: Total allogenic blood transfusion				
General surgery (Intercept)	895.745	75.264	11.901	< 0.001
Percentage of CS transfusion from total	-7.674	1.313	-5.844	< 0.001
volume of transfusion in general surgery				
Orthopedic surgery (Intercept)	762.345	118.982	6.407	< 0.001
Percentage of CS transfusion from total	-1.983	2.659	-0.746	0.456
volume of transfusion in Orthopedic surgery				
DV: Total cost				
General surgery (Intercept)	642.224	47.035	13.654	< 0.001
Percentage of CS transfusion from total	-4.026	0.821	-4.906	< 0.001
volume of transfusion in general surgery				
Orthopedic surgery (Intercept)	467.573	74.357	6.288	< 0.001
Percentage of CS transfusion from total	-1.120	1.661	-0.674	0.501
volume of transfusion in Orthopedic surgery				



Results: CS was successfully used in 97% of cardiac and 74% of trauma cases. The proportion of blood requirements provided by CS, compared to allogenic transfusion, was also significantly higher in cardiac surgery. However, there was still net benefit for CS in trauma surgery, with median salvaged transfusion volume of at least one unit, in both general & orthopedic trauma.

Note: CS deployment is \$70. CS deployment + auto-transfusion is \$150. One unit of pRBC is \$210.

Conclusion: The controlled setting of cardiac surgery leads to greater success at retrieving and transfusing salvaged blood than in trauma surgery. However, CS deployment in trauma surgery is feasible in many cases and reduces the need for allogenic transfusion.



*mean ± standard deviation